Search Result

Results for "

glucagon receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GCGR (86) Adenylate Cyclase (1) Akt (5) AMPK (1) Amylin Receptor (2) Apoptosis (4) Arrestin (1) Autophagy (1) CGRP Receptor (1) Cytochrome P450 (2) Drug Derivative (1) Drug Intermediate (1) Endogenous Metabolite (1) Free Fatty Acid Receptor (1) FXR (4) G Protein-coupled Receptor Kinase (GRK) (1) GLP Receptor (72) Glucocorticoid Receptor (1) Insulin Receptor (7) Interleukin Related (1) Isotope-Labeled Compounds (7) MEK (3) Melatonin Receptor (1) MMP (3) Neuropeptide Y Receptor (1) Nuclear Hormone Receptor 4A/NR4A (4) Orphan GPCR (1) p38 MAPK (1) PACAP Receptor (2) Phosphodiesterase (PDE) (1) PI3K (1) Reactive Oxygen Species (ROS) (4) Reference Standards (6) Sirtuin (1) Somatostatin Receptor (4)
By Research Areas:	Cancer (7) Cardiovascular Disease (12) Endocrinology (4) Inflammation/Immunology (24) Metabolic Disease (147) Neurological Disease (12)

By Targets:

GCGR (86)

Adenylate Cyclase (1)

Akt (5)

AMPK (1)

Amylin Receptor (2)

Apoptosis (4)

Arrestin (1)

Autophagy (1)

CGRP Receptor (1)

Cytochrome P450 (2)

Drug Derivative (1)

Drug Intermediate (1)

Endogenous Metabolite (1)

Free Fatty Acid Receptor (1)

FXR (4)

G Protein-coupled Receptor Kinase (GRK) (1)

GLP Receptor (72)

Glucocorticoid Receptor (1)

Insulin Receptor (7)

Interleukin Related (1)

Isotope-Labeled Compounds (7)

MEK (3)

Melatonin Receptor (1)

MMP (3)

Neuropeptide Y Receptor (1)

Nuclear Hormone Receptor 4A/NR4A (4)

Orphan GPCR (1)

p38 MAPK (1)

PACAP Receptor (2)

Phosphodiesterase (PDE) (1)

PI3K (1)

Reactive Oxygen Species (ROS) (4)

Reference Standards (6)

Sirtuin (1)

Somatostatin Receptor (4)

By Research Areas:

Cancer (7)

Cardiovascular Disease (12)

Endocrinology (4)

Inflammation/Immunology (24)

Metabolic Disease (147)

Neurological Disease (12)

166

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: GCGR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3506

Retatrutide 3 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P0014

Liraglutide 35+ Cited Publications	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-112185

Orforglipron 1 Publications Verification LY3502970; GLP-1 receptor agonist 1	GCGR	Metabolic Disease Inflammation/Immunology
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete .

HY-125824

Danuglipron 4 Publications Verification PF-06882961	GCGR	Metabolic Disease
Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research .

HY-P0120

Dulaglutide 1 Publications Verification LY2189265	GCGR	Metabolic Disease
Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-13443A

Exendin-4 acetate Maximum Cited Publications 66 Publications Verification Exenatide acetate	GCGR	Cardiovascular Disease Metabolic Disease Cancer
Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting *glucagon-like* peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

HY-50663

MK 0893 5+ Cited Publications	GCGR	Metabolic Disease
MK 0893 is a potent and selective **glucagon receptor antagonist with an IC₅₀** of 6.6 nM.

HY-19904

Adomeglivant 4 Publications Verification LY2409021	GCGR	Metabolic Disease
Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus .

HY-P3366

Ecnoglutide XW003	GCGR	Metabolic Disease
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity .

HY-P3506A

Retatrutide TFA 3 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-103546

BETP 1 Publications Verification	GCGR	Metabolic Disease
BETP is an agonist of **glucagon-like peptide-1 (GLP-1) receptor, with EC₅₀*s of 0.66 and 0.755 μM for human and rat GLP-1 receptor*, respectively.

HY-19947

PF-06291874 1 Publications Verification glucagon receptor antagonists-4	GCGR	Metabolic Disease
PF-06291874 is a highly potent, non-peptide and orally active **glucagon receptor** antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .

HY-13443

Exendin-4 Maximum Cited Publications 66 Publications Verification Exenatide	GCGR	Cardiovascular Disease Metabolic Disease Cancer
Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting *glucagon-like* peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

HY-12525

LGD-6972	GCGR	Metabolic Disease
LGD-6972 is a selective and orally active **glucagon receptor** antagonist. LGD-6972 has the potential for type 2 diabetes research .

HY-P1782

Calcitonin (8-32), salmon	Amylin Receptor	Metabolic Disease
Calcitonin (8-32), salmon is a highly selective Amylin receptor antagonist. Calcitonin (8-32), salmon reverses the Amylin-mediated inhibition of glucose-induced insulin release, but has no effect on either glucagon release or somatostatin release. Calcitonin (8-32), salmon can be used for studies related to β-cell amylin .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-P99357

Crotedumab REGN1193; Anti-GCGR Reference Antibody (crotedumab)	GCGR	Metabolic Disease
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a K_D of 0.1 nM. Crotedumab can be used for the research of diabetes .

HY-156968

GLP-1 receptor agonist 14	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 14 (compound 474) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 14 plays an important role in diabetes or other metabolic disorders .

HY-124622

NNC-0640	GCGR	Metabolic Disease
NNC-0640 is an effective negative allosteric modulator (NAM) of the human glucagon receptor (GCGR), with an IC₅₀ value of 69.2 nM. NNC-0640 holds potential for research in the field of diabetes .

HY-103547

L-168049 1 Publications Verification	GCGR	Metabolic Disease
L-168049 is a potent, selective, orally active and non-competitive **glucagon receptor antagonist with IC₅₀*s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon* receptors, respectively .

HY-112679

GLP-1 receptor agonist 2	GCGR	Inflammation/Immunology
GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist .

HY-P1145

Glucagon-like peptide 1 (1-37), human 1 Publications Verification GLP-1 (1-37) human	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P10957

Imapextide MBX 1416	GLP Receptor	Metabolic Disease
Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that can be used in hypoglycemia research .

HY-P11271

Ribupatide	Insulin Receptor GLP Receptor	Metabolic Disease
Ribupatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .

HY-145458

PF-06954522 GLP-1 receptor agonist 9	GLP Receptor	Metabolic Disease
PF-06954522 is a glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06954522 is applicable to research related to type 2 diabetes .

HY-N0630

Shanzhiside methyl ester 1 Publications Verification	GCGR	Neurological Disease
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule **glucagon-like peptide-1 (GLP-1) receptor** agonist and has the ability to induce anti-allodynic tolerance .

HY-50675

GRA Ex-25	GCGR	Metabolic Disease
GRA Ex-25 is an inhibitor of **glucagon receptor, with IC₅₀** of 56 and 55 nM for rat and human glucagon receptors, respectively.

HY-148844

GCGR antagonist 2	GCGR	Metabolic Disease
GCGR antagonist 2, a Furan-2-carbohydrazide, is an orally active **glucagon receptor antagonist. GCGR antagonist 2 binds to hGluR with an K_d** value of 2.3 nM, and inhibits rat receptor with an IC₅₀ value of 0.43 nM. GCGR antagonist 2 inhibits glucagon-stimulated glycogenolysis .

HY-P1145A

Glucagon-like peptide 1 (1-37), human TFA 1 Publications Verification HuGLP-1 TFA	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.

HY-P10271

RG7697 NNC0090-2746; MAR709; RO6811135	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .

HY-P1144

Oxyntomodulin (bovine, porcine) glucagon-37 (bovine, porcine)	GCGR	Metabolic Disease
Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-P99383

Volagidemab REMD-477; AMG-477	GCGR	Metabolic Disease
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .

HY-P0165

Taspoglutide ITM077; R1583; BIM51077	GCGR	Metabolic Disease
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC₅₀ value of 0.06 nM.

HY-50159

Glucagon receptor antagonist-3	GCGR	Metabolic Disease
Glucagon receptor antagonist-3 is a highly potent glucagon receptor antagonist.

HY-P10032

NN1177 NNC9204-1177	GCGR GLP Receptor Cytochrome P450	Metabolic Disease
NN1177 is a long-acting **GLP-1/glucagon receptor** co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P990013

Gulgafafusp alfa Glutazumab; GMA-102; GMA-105	GCGR	Metabolic Disease
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .

HY-P0014B

Liraglutide TFA 35+ Cited Publications	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-139276

Pal-Glu(OSu)-OH	GLP Receptor	Others
Pal-Glu(OSu)-OH is a side chain of Liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used for type 2 diabetes mellitus research .

HY-10036

Glucagon receptor antagonist-1	GCGR	Metabolic Disease
Glucagon receptor antagonist-1 is a highly potent glucagon receptor antagonist.

HY-50158

Glucagon receptor antagonist-2	GCGR	Metabolic Disease
Glucagon receptor antagonist-2 is a highly potent glucagon receptor antagonist.

HY-P1143A

[Des-His1,Glu9]-Glucagon amide TFA	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the **glucagon receptor, with a pA₂** of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes .

HY-P2497

Exendin (5-39) 1 Publications Verification	GCGR	Neurological Disease
Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats .

HY-116930

S-20928	Melatonin Receptor	Metabolic Disease
S-20928 is an antagonist for melatonin receptor through inhibition of binding of melatonin to its receptors. S-20928 enhances the 2-Deoxy-D-glucose (2DG) (HY-13966)-induced increase in blood glucose and glucagon levels in rats brain .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-P1143

[Des-His1,Glu9]-Glucagon amide	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the **glucagon receptor, with a pA₂** of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes .

HY-P10591

Olatorepatide Olatorepatidum	Insulin Receptor GLP Receptor	Metabolic Disease
Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library

1,113 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 1,113 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Target	Research Area	Image

HY-P99357

Crotedumab REGN1193; Anti-GCGR Reference Antibody (crotedumab)	GCGR	Metabolic Disease
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a K_D of 0.1 nM. Crotedumab can be used for the research of diabetes .

HY-P99383

Volagidemab REMD-477; AMG-477	GCGR	Metabolic Disease
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .

HY-P990013

Gulgafafusp alfa Glutazumab; GMA-102; GMA-105	GCGR	Metabolic Disease
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .

HY-P992007

PF-06293620 RN909	GCGR	Metabolic Disease
PF-06293620 (RN909) is a monoclonal antibody antagonist of the **glucagon receptor**. PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N15721

Tryptophan-cholic acid Trp-CA	Triterpenes Structural Classification Terpenoids Endogenous metabolite Source Classification	Orphan GPCR GLP Receptor
Tryptophan-cholic acid (Trp-CA) is a microbial amino acid-conjugated bile acid that acts as an endogenous ligand and agonist (EC₅₀=9.6 μM) for the orphan G protein-coupled receptor (GPCR) MRGPRE (Mas-related G protein-coupled receptor family member E). Tryptophan-cholic acid is orally effective but has poor oral absorption and does not cross the blood-brain barrier. Tryptophan-cholic acid promotes the secretion of glucagon-like peptide GLP-1, thereby improving glucose tolerance in diabetic mice. Tryptophan-cholic acid improves glucose tolerance, promotes insulin secretion, and alleviates high-fat diet-induced hepatic steatosis without causing pruritus side effects. Tryptophan-cholic acid is primarily used in research on type 2 diabetes (T2D) .

HY-N0630

Shanzhiside methyl ester 1 Publications Verification	Iridoids Terpenoids Labiatae Phaseolus lunatus L. Plants Source Classification	GCGR
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule **glucagon-like peptide-1 (GLP-1) receptor** agonist and has the ability to induce anti-allodynic tolerance .

HY-119739

Skyrin 1 Publications Verification	Ventilago leiocarpa Benth. Quinones Anthraquinones Plants Rhamnaceae Source Classification	GCGR
Skyrin is an anthraquinone compound that can be isolated from almond fruit. Skyrin is a receptor-selective *glucagon* antagonist. Skyrin can inhibit the growth of tumor cells .

HY-N0630R

Shanzhiside methyl ester (Standard)	Structural Classification Iridoids Terpenoids Labiatae Phaseolus lunatus L. Plants Source Classification	Reference Standards GCGR
Shanzhiside methyl ester (Standard) is the analytical standard of Shanzhiside methyl ester. This product is intended for research and analytical applications. Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .

HY-113513

5-HEPE	Microorganisms Source Classification	Others
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

Recombinant Proteins Recommended:

Glucagon Receptor

Species:	Human (10) Rat (2) Mouse (3) Cynomolgus (1)
Tag:	SUMO (1) His (12) Tag Free (1) Avi (3) Myc (2) Fc (3)
Source:	HEK293 (15) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P78702

	*GCGR/Glucagon* receptor Protein, Mouse (HEK293, Fc)** glucagon R; GCGR; glucagon receptor	Mouse	HEK293
	GCGR/glucagon receptor protein is a G protein-coupled receptor for glucagon that centrally regulates blood glucose levels. It plays a key role in the fasting response by actively regulating hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. GCGR/Glucagon receptor Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived GCGR/Glucagon receptor protein, expressed by HEK293 , with C-hFc labeled tag. The total length of GCGR/Glucagon receptor Protein, Mouse (HEK293, Fc) is 111 a.a., with molecular weight of 50-65 kDa.

HY-P703987

	GCGR Protein, Human (HEK293, His, Avi) glucagon receptor; GL-R; GCGR; glucagon R	Human	HEK293
	The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, His, Avi) is the recombinant human-derived GCGR protein, expressed by HEK293, with C-Avi and C-His labeled tag.

HY-P703992

	GCGR Protein, Human (HEK293, hFc) glucagon receptor; GL-R; GCGR; glucagon R	Human	HEK293
	The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, hFc) is the recombinant human-derived GCGR protein, expressed by HEK293, with C-hFc labeled tag.

HY-P705976

	GCGR Protein, Rat (HEK293, His) glucagon receptor; GL-R; Gcgr	Rat	HEK293

HY-P704627

	GCGR Protein-VLP, Human (HEK293) glucagon receptor; GGR; GL-R; FLJ97182; MGC138246;	Human	HEK293
	GCGR Protein-VLP, Human (HEK293) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.

HY-P704626

	GCGR Protein, Human (HEK293, His) glucagon receptor; GGR; GL-R; FLJ97182; MGC138246;	Human	HEK293
	The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, His) is the recombinant human-derived GCGR protein, expressed by HEK293, with C-His labeled tag.

HY-P705157

	GCGR Protein, Human (Biotinylated, HEK293, His-Avi) glucagon receptor; GGR; GL-R; FLJ97182; MGC138246;	Human	HEK293

HY-P700411

	GCGR Protein, Human (HEK293, N-His, C-Myc) glucagon receptor; GGR; GL-R; FLJ97182; MGC138246;	Human	HEK293
	The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GCGR protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag.

HY-P705973

	GLP1R Protein, Cynomolgus (HEK293, His) glucagon-like peptide 1 receptor; GLP1R	Cynomolgus	HEK293

HY-P72206

	GLP1R Protein, Mouse (His-SUMO) Glp1r; glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R; GLP-1R	Mouse	E. coli
	GLP1R protein, a G-protein coupled receptor, binds to GLP-1, activating adenylyl cyclase and increasing intracellular cAMP levels. This interaction regulates insulin secretion and maintains glucose homeostasis. GLP1R can also form dimers with GIPR, suggesting complex regulatory mechanisms and interactions with other receptors. GLP1R Protein, Mouse (His-SUMO) is the recombinant mouse-derived GLP1R protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.

HY-P705621

	GLP1R Protein, Mouse (HEK293, His) Glp1r; glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R; GLP-1R	Mouse	HEK293

HY-P70352

	GLP1R Protein, Human (HEK293, Fc) rHuglucagon-like peptide 1 receptor/GLP1R, Fc; glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R	Human	HEK293
	The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, Fc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P704635

	GLP1R Protein, Human (HEK293, His) rHuglucagon-like peptide 1 receptor/GLP1R, Fc; glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R	Human	HEK293
	The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, His) is the recombinant human-derived GLP1R protein, expressed by HEK293, with C-His labeled tag.

HY-P705301

	GLP1R Protein, Human (Biotinylated, HEK293, His-Avi) rHuglucagon-like peptide 1 receptor/GLP1R, Fc; glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R	Human	HEK293

HY-P705977

	GLP1R Protein, Rat (HEK293, His) glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R; GLP-1R; Glp1r; Glpr	Rat	HEK293

HY-P700468

	GLP1R Protein, Human (HEK293, N-His, C-Myc) 2 Publications Verification rHuglucagon-like peptide 1 receptor/GLP1R, Fc; glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R	Human	HEK293
	The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-P0014S1

Liraglutide-13C5,15N tetraTFA
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P0014AS

Liraglutide-d8 tetraTFA
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a **glucagon-like peptide-1 (GLP-1) receptor** agonist used for the study of type 2 diabetes mellitus .

HY-P1624S1

Teduglutide-Leu(13C6,15N) sodium

Teduglutide-Leu( ¹³C₆, ¹⁵N) (ALX-0600-Leu( ¹³C₆, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-P0014S2

Liraglutide-13C6,15N TFA
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-13443S

Exendin-4 (Leu-13C6,15N) TFA
Exendin-4 (Leu- ¹³C₆, ¹⁵N) (Exenatide (Leu- ¹³C₆, ¹⁵N)) TFA is the ¹³C- and ¹⁵N-labeled Exendin-4 TFA (HY-13443). Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC₅₀ of 3.22 nM .

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA

Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis .

HY-P1624S

Teduglutide-Ala(13C3,15N) sodium

Teduglutide-Ala( ¹³C₃, ¹⁵N) (ALX-0600-Ala( ¹³C₃, ¹⁵N)) sodium is the ¹³C- and ¹⁵N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81160

	GLP-1R Antibody 1 Publications Verification glucagon like peptide-1 receptor; GLP 1 R; GLP 1 receptor; GLP 1R; Glp1r; GLP; glp1r; glucagon like peptide 1 receptor; RATGL1RCP; Glip; MGC138331; GLP-1-R; GLP1R_HUMAN; glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R; GLP-1R; Precursor.	WB, IHC-P, IHC-F, ICC/IF, FC	Human, Mouse, Rat
	GLP-1R Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to GLP-1R.